Allan H. Friedman

<i>IDH1</i>and<i>IDH2</i>Mutations in Gliomas

Hai Yan, D. Williams Parsons, Genglin Jin et al. · New England Journal of Medicine · 2009 · 5.9K citations · Full text

Medicine, Genetics, Oncology +16

Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

James J. Vredenburgh, Annick Desjardins, James E. Herndon et al. · Journal of Clinical Oncology · 2007 · 1.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

Patrick Killela, Zachary J. Reitman, Yuchen Jiao et al. · Proceedings of the National Academy of Sciences · 2013 · 1.4K citations · Full text

Medicine, Genetics, Oncology +17

Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

James J. Vredenburgh, Annick Desjardins, James E. Herndon et al. · Clinical Cancer Research · 2007 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

John H. Sampson, Amy B. Heimberger, Gary E. Archer et al. · Journal of Clinical Oncology · 2010 · 808 citations · Full text

Medicine, Immunology, Oncology +17